BlackRock and Nextech betting on radiopharma with ITM

ITM supplies Novartis with an agent for its Pluvicto radiopharmaceutical, which reached sales of $211m in the first quarter.

3 July 2023•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.